错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Cost-effectiveness and cost-utility analysis of a nurse-led, transitional care model to improve care coordination for patients with cardiovascular diseases: results from the “Cardiolotse” study

  • Marie Coors,
  • Wiebke Schüttig,
  • Katrin C. Reber,
  • Harald Darius,
  • Alfred Holzgreve,
  • Sebastian Karmann,
  • Anica Stürtz,
  • Rebecca Zöller,
  • Saskia Kropp,
  • Petra Riesner,
  • Leonie Sundmacher

摘要

Objective

To assess the 12-month cost-effectiveness of the nurse-led transitional care program “Cardiolotse” (CL) for patients with cardiovascular diseases compared to usual care (UC).

Methods

A cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) were conducted from the perspective of statutory health insurance (SHI), covering a time horizon of 12 months. Analyzed outcomes included the number of rehospitalizations and health-related quality of life (HRQoL). Total costs comprised program costs and the utilization of healthcare resources. Point estimates are presented as incremental cost-effectiveness ratios (ICERs) and incremental cost-utility ratios (ICURs). Sensitivity and subgroup analyses were conducted to illustrate uncertainty and provide insights into the impact mechanisms of the CL program.

Results

The study population consisted of 2550 patients, with 1256 allocated to the intervention group and 1294 to the control group. Patients who received support from CLs experienced fewer rehospitalizations and lower inpatient costs from an SHI perspective, compared to the UC group. HRQoL assessments indicated higher utility values for CL patients at the 12-month follow-up. Total program costs amounted to €1454.65 per patient. The CEA and CUA demonstrate that the CL program is dominant compared to UC from the SHI perspective.

Conclusion

Our study shows that the CL program not only reduces the number of rehospitalizations and costs but increases HRQoL, resulting in a dominant ICER and ICUR. Further research is necessary to evaluate longer periods of time, different levels of care intensity, and perspectives of different healthcare stakeholders.

Trial registration

German Clinical Trial Register DRKS00020424, 2020-06-18, retrospectively registered.